Zota Health Care LImited (ZOTA) - Net Assets
Based on the latest financial reports, Zota Health Care LImited (ZOTA) has net assets worth Rs3.19 Billion INR (≈ $34.48 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs6.06 Billion ≈ $65.53 Million USD) and total liabilities (Rs2.87 Billion ≈ $31.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zota Health Care LImited liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs3.19 Billion |
| % of Total Assets | 52.63% |
| Annual Growth Rate | 24.83% |
| 5-Year Change | 242.63% |
| 10-Year Change | 880.36% |
| Growth Volatility | 63.73 |
Zota Health Care LImited - Net Assets Trend (2012–2025)
This chart illustrates how Zota Health Care LImited's net assets have evolved over time, based on quarterly financial data. Also explore Zota Health Care LImited total assets for the complete picture of this company's asset base.
Annual Net Assets for Zota Health Care LImited (2012–2025)
The table below shows the annual net assets of Zota Health Care LImited from 2012 to 2025. For live valuation and market cap data, see ZOTA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.27 Billion ≈ $24.57 Million |
+152.46% |
| 2024-03-31 | Rs899.77 Million ≈ $9.73 Million |
+11.97% |
| 2023-03-31 | Rs803.57 Million ≈ $8.69 Million |
-10.34% |
| 2022-03-31 | Rs896.27 Million ≈ $9.69 Million |
+35.19% |
| 2021-03-31 | Rs662.97 Million ≈ $7.17 Million |
-3.68% |
| 2020-03-31 | Rs688.29 Million ≈ $7.44 Million |
-0.14% |
| 2019-03-31 | Rs689.25 Million ≈ $7.45 Million |
-1.22% |
| 2018-03-31 | Rs697.78 Million ≈ $7.55 Million |
+206.58% |
| 2017-03-31 | Rs227.60 Million ≈ $2.46 Million |
-1.77% |
| 2016-03-31 | Rs231.71 Million ≈ $2.51 Million |
+28.00% |
| 2015-03-31 | Rs181.02 Million ≈ $1.96 Million |
+15.97% |
| 2014-03-31 | Rs156.09 Million ≈ $1.69 Million |
+12.54% |
| 2013-03-31 | Rs138.70 Million ≈ $1.50 Million |
+9.16% |
| 2012-03-31 | Rs127.07 Million ≈ $1.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zota Health Care LImited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 595.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs286.35 Million | 12.80% |
| Other Components | Rs2.14 Billion | 95.78% |
| Total Equity | Rs2.24 Billion | 100.00% |
Zota Health Care LImited Competitors by Market Cap
The table below lists competitors of Zota Health Care LImited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gravity Co Ltd
NASDAQ:GRVY
|
$430.14 Million |
|
Samse SA
PA:SAMS
|
$430.15 Million |
|
Novavest Real Estate Ag
SW:NREN
|
$430.23 Million |
|
Movado Group Inc
NYSE:MOV
|
$430.48 Million |
|
Touchstone International Medical Science Co Ltd
SHG:688013
|
$430.02 Million |
|
Styrenix Performance Materials Limited
NSE:STYRENIX
|
$429.98 Million |
|
Duni AB
ST:DUNI
|
$429.92 Million |
|
Kangping Technology (Suzhou) Co. Ltd.
SHE:300907
|
$429.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zota Health Care LImited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 899,766,000 to 2,236,848,000, a change of 1,337,082,000 (148.6%).
- Net loss of 563,984,000 reduced equity.
- Dividend payments of 27,408,000 reduced retained earnings.
- Share repurchases of 406,222,000 reduced equity.
- New share issuances of 1,889,793,000 increased equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 444,904,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs-563.98 Million | -25.21% |
| Dividends Paid | Rs27.41 Million | -1.23% |
| Share Repurchases | Rs406.22 Million | -18.16% |
| Share Issuances | Rs1.89 Billion | +84.48% |
| Other Comprehensive Income | Rs-1.00K | -0.0% |
| Other Changes | Rs444.90 Million | +19.89% |
| Total Change | Rs- | 148.60% |
Book Value vs Market Value Analysis
This analysis compares Zota Health Care LImited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 253.44x to 16.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-03-31 | Rs5.17 | Rs1311.20 | x |
| 2013-03-31 | Rs6.90 | Rs1311.20 | x |
| 2014-03-31 | Rs7.76 | Rs1311.20 | x |
| 2015-03-31 | Rs9.00 | Rs1311.20 | x |
| 2016-03-31 | Rs10.72 | Rs1311.20 | x |
| 2017-03-31 | Rs9.27 | Rs1311.20 | x |
| 2018-03-31 | Rs28.99 | Rs1311.20 | x |
| 2019-03-31 | Rs28.06 | Rs1311.20 | x |
| 2020-03-31 | Rs28.02 | Rs1311.20 | x |
| 2021-03-31 | Rs26.99 | Rs1311.20 | x |
| 2022-03-31 | Rs36.02 | Rs1311.20 | x |
| 2023-03-31 | Rs31.94 | Rs1311.20 | x |
| 2024-03-31 | Rs34.81 | Rs1311.20 | x |
| 2025-03-31 | Rs81.42 | Rs1311.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zota Health Care LImited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19.25%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.96x
- Recent ROE (-25.21%) is below the historical average (7.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 15.61% | 5.27% | 1.32x | 2.24x | Rs7.13 Million |
| 2013 | 18.42% | 5.82% | 1.49x | 2.12x | Rs11.68 Million |
| 2014 | 20.05% | 6.25% | 1.51x | 2.13x | Rs15.69 Million |
| 2015 | 23.54% | 7.55% | 1.47x | 2.12x | Rs24.50 Million |
| 2016 | 23.70% | 7.89% | 1.47x | 2.04x | Rs29.53 Million |
| 2017 | 24.35% | 7.74% | 1.33x | 2.36x | Rs32.65 Million |
| 2018 | 10.42% | 9.34% | 0.85x | 1.32x | Rs2.90 Million |
| 2019 | 8.05% | 6.51% | 0.95x | 1.30x | Rs-13.44 Million |
| 2020 | 3.98% | 2.88% | 1.07x | 1.29x | Rs-41.41 Million |
| 2021 | -0.32% | -0.20% | 1.25x | 1.29x | Rs-68.39 Million |
| 2022 | 9.94% | 6.79% | 0.94x | 1.55x | Rs-550.80K |
| 2023 | -7.18% | -4.12% | 0.89x | 1.97x | Rs-138.08 Million |
| 2024 | -15.95% | -7.95% | 0.79x | 2.54x | Rs-233.46 Million |
| 2025 | -25.21% | -19.25% | 0.67x | 1.96x | Rs-787.67 Million |
Industry Comparison
This section compares Zota Health Care LImited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,414,031,375
- Average return on equity (ROE) among peers: 8.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zota Health Care LImited (ZOTA) | Rs3.19 Billion | 15.61% | 0.90x | $430.12 Million |
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | $2.01 Billion | -1.19% | 0.28x | $15.90 Million |
| Blue Jet Healthcare Limited (BLUEJET) | $6.81 Billion | 23.48% | 0.26x | $833.96 Million |
| Concord Biotech Limited (CONCORDBIO) | $11.03 Billion | 15.86% | 0.19x | $1.29 Billion |
| Dishman Carbogen Amcis Limited (DCAL) | $55.49 Billion | 0.32% | 0.56x | $310.59 Million |
| Lyka Labs Limited (LYKALABS) | $-151.11 Million | 0.00% | 0.00x | $23.04 Million |
| SMS Lifesciences India Limited (SMSLIFE) | $1.94 Billion | 4.70% | 1.02x | $42.13 Million |
| Supriya Lifescience Limited (SUPRIYA) | $6.16 Billion | 24.66% | 0.19x | $604.83 Million |
| Take Solutions Limited (TAKE) | $20.00 Million | 0.00% | 0.50x | $67.51 Million |
About Zota Health Care LImited
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers generic drugs, health supplements, over-the-counter products, wellness and ayurvedic products, and nutraceutical products. It provides various medicines for chronic ailments, such as diabetes, cardiac, and thyroid disorders. The company operates its retail stores u… Read more